10 results · 32ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

QIAGEN GmbH

Manufacturer
🇩🇪 Germany·TÜV Rheinland LGA Products GmbH

QIAGEN, GMBH

FDA registration
QIAGEN, GMBH·16 products·🇩🇪 Germany

QIAGEN GmbH

Authorized representative
🇩🇪 Germany·2 Manufacturers

HX 1782924-1

Certificate
IVDR QMS·QIAGEN GmbH·TÜV Rheinland LGA Products GmbH

EZ1 DSP Virus Kit (48), IVD, REF 62724 intended for in vitro diagnostic use.

FDA Enforcement
Class II ·Terminated·QIAGEN·August 8, 2018

QIAamp DSP Virus Kit Cat. No. 60704

FDA Enforcement
Class II ·Terminated·Qiagen, GmbH·December 27, 2017

therascreen ¿KRAS RGQ PCR Kit (24)-IVD qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of seven somatic mutations in the human KRAS oncogene REF 870021 (US IVD)

FDA Enforcement
Class II ·Ongoing·Qiagen GmbH·October 11, 2023

QIAstat-Dx¿ Respiratory SARS-CoV-2 Panel -IVD intended for the detection and differentiation of nucleic acid from SARS-CoV-2 and the following organism types and subtypes: Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, SARS-CoV-2, Human Metapneumovirus A+B, Influenza A, Influenza A H1, Influenza A H3, Influenza A H1N1/pdm09, Influenza B, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Rhinovirus/Enterovirus, Respiratory Syncytial Virus A+B, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae REF 691223

FDA Enforcement
Class II ·Ongoing·Qiagen GmbH·August 2, 2023

QIAstat-Dx Respiratory SARS-CoV-2 Panel -US IVD qualitative test intended for analyzing nasopharyngeal swab (NPS) samples from patients suspected of respiratory infection for the presence of viral or bacterial nucleic acids REF 691223

FDA Enforcement
Class II ·Ongoing·Qiagen GmbH·August 2, 2023

QIAstat-Dx Respiratory SARS-CoV-2 Panel (V1 and V2, CE IVD, not US IVD, not sold in the US.) Qualitative test intended for analyzing nasopharyngeal swab (NPS) samples from patients suspected of respiratory infection REF: 691214

FDA Enforcement
Class II ·Ongoing·Qiagen GmbH·August 2, 2023